Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Altimmune (ALT) Shares Outstanding (Diluted Average) (2016 - 2025)

Altimmune (ALT) has disclosed Shares Outstanding (Diluted Average) for 9 consecutive years, with $88.1 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding (Diluted Average) rose 24.08% to $88.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $88.1 million through Dec 2025, up 24.08% year-over-year, with the annual reading at $88.1 million for FY2025, 24.08% up from the prior year.
  • Shares Outstanding (Diluted Average) for Q4 2025 was $88.1 million at Altimmune, up from $82.2 million in the prior quarter.
  • The five-year high for Shares Outstanding (Diluted Average) was $88.1 million in Q4 2025, with the low at $38.9 million in Q1 2021.
  • Average Shares Outstanding (Diluted Average) over 5 years is $58.3 million, with a median of $52.0 million recorded in 2023.
  • The sharpest move saw Shares Outstanding (Diluted Average) skyrocketed 61.03% in 2021, then increased 6.7% in 2025.
  • Over 5 years, Shares Outstanding (Diluted Average) stood at $41.3 million in 2021, then rose by 13.67% to $46.9 million in 2022, then grew by 13.47% to $53.2 million in 2023, then skyrocketed by 33.35% to $71.0 million in 2024, then increased by 24.08% to $88.1 million in 2025.
  • According to Business Quant data, Shares Outstanding (Diluted Average) over the past three periods came in at $88.1 million, $82.2 million, and $81.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.